Eli Lilly and Company (LLY)

 

For the full year of 2008, we expect earnings per share to be in the range of $3.80 to $3.95. This guidance includes the anticipated acquired in-process research and development charges of $.05 related to the BioMS in-licensing agreement. We expect sales to grow in the mid-to high-single digits, driven primarily by increased volume and strong sales growth for Cymbalta, Cialis, Byetta, Alimta, and Humalog. We expect modest improvement in gross margin as a percent of net sales, driven primarily by manufacturing expenses growing more slowly than sales. In addition, we expect operating expenses to grow more slowly than sales in 2008, with growth in the mid-single digits. Marketing, selling, and administrative expenses are expected to grow in the low-single digits, driven by investments in prasugrel, Cymbalta, Evista for invasive breast cancer risk reduction, Humalog, and Byetta, offset by decreases in other areas. Research and development expenses are expected to grow in the high-single to low-double digits. Other income — net is expected to contribute less than $100 million. The effective tax rate is expected to be approximately 23 percent. We expect capital expenditures of approximately $1.1 billion.

 

Actual results could differ materially and will depend on, among other things, the continuing growth of our currently marketed products; developments with competitive products; the timing and scope of regulatory approvals and the success of our new product launches; asset impairments, restructurings, and acquisitions of compounds under development resulting in acquired in-process research and development charges; foreign exchange rates; changes in effective tax rates; wholesaler inventory changes; other regulatory developments, litigation, and government investigations; and the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals. We undertake no duty to update these forward-looking statements.

 

 

For the full year of 2008, we expect earnings per share to be in
the range of $3.80 to $3.95. This guidance includes the
anticipated acquired in-process research and development charges
of $.05 related to the BioMS in-licensing agreement. We expect
sales to grow in the mid-to high-single digits, driven primarily
by increased volume and strong sales growth for Cymbalta,
Cialis, Byetta, Alimta, and Humalog. We expect modest
improvement in gross margin as a percent of net sales, driven
primarily by manufacturing expenses growing more slowly than
sales. In addition, we expect operating expenses to grow more
slowly than sales in 2008, with growth in the mid-single digits.
Marketing, selling, and administrative expenses are expected to
grow in the low-single digits, driven by investments in
prasugrel, Cymbalta, Evista for invasive breast cancer risk
reduction, Humalog, and Byetta, offset by decreases in other
areas. Research and development expenses are expected to grow in
the high-single to low-double digits. Other income —
net is expected to contribute less than $100 million. The
effective tax rate is expected to be approximately
23 percent. We expect capital expenditures of approximately
$1.1 billion.

 

Actual results could differ materially and will depend on, among
other things, the continuing growth of our currently marketed
products; developments with competitive products; the timing and
scope of regulatory approvals and the success of our new product
launches; asset impairments, restructurings, and acquisitions of
compounds under development resulting in acquired in-process
research and development charges; foreign exchange rates;
changes in effective tax rates; wholesaler inventory changes;
other regulatory developments, litigation, and government
investigations; and the impact of governmental actions regarding
pricing, importation, and reimbursement for pharmaceuticals. We
undertake no duty to update these forward-looking statements.

 

 

For the full year of 2008, we expect earnings per share to be in the range of $3.80 to $3.95. This guidance includes the anticipated acquired in-process research and development charges of $.05 related to the BioMS in-licensing agreement. We expect sales to grow in the mid-to high-single digits, driven primarily by increased volume and strong sales growth for Cymbalta, Cialis, Byetta, Alimta, and Humalog. We expect modest improvement in gross margin as a percent of net sales, driven primarily by manufacturing expenses growing more slowly than sales. In addition, we expect operating expenses to grow more slowly than sales in 2008, with growth in the mid-single digits. Marketing, selling, and administrative expenses are expected to grow in the low-single digits, driven by investments in prasugrel, Cymbalta, Evista for invasive breast cancer risk reduction, Humalog, and Byetta, offset by decreases in other areas. Research and development expenses are expected to grow in the high-single to low-double digits. Other income — net is expected to contribute less than $100 million. The effective tax rate is expected to be approximately 23 percent. We expect capital expenditures of approximately $1.1 billion.

 

Actual results could differ materially and will depend on, among other things, the continuing growth of our currently marketed products; developments with competitive products; the timing and scope of regulatory approvals and the success of our new product launches; asset impairments, restructurings, and acquisitions of compounds under development resulting in acquired in-process research and development charges; foreign exchange rates; changes in effective tax rates; wholesaler inventory changes; other regulatory developments, litigation, and government investigations; and the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals. We undertake no duty to update these forward-looking statements.

 

 

For the full year of 2008, we expect earnings per share to be in
the range of $3.80 to $3.95. This guidance includes the
anticipated acquired in-process research and development charges
of $.05 related to the BioMS in-licensing agreement. We expect
sales to grow in the mid-to high-single digits, driven primarily
by increased volume and strong sales growth for Cymbalta,
Cialis, Byetta, Alimta, and Humalog. We expect modest
improvement in gross margin as a percent of net sales, driven
primarily by manufacturing expenses growing more slowly than
sales. In addition, we expect operating expenses to grow more
slowly than sales in 2008, with growth in the mid-single digits.
Marketing, selling, and administrative expenses are expected to
grow in the low-single digits, driven by investments in
prasugrel, Cymbalta, Evista for invasive breast cancer risk
reduction, Humalog, and Byetta, offset by decreases in other
areas. Research and development expenses are expected to grow in
the high-single to low-double digits. Other income —
net is expected to contribute less than $100 million. The
effective tax rate is expected to be approximately
23 percent. We expect capital expenditures of approximately
$1.1 billion.

 

Actual results could differ materially and will depend on, among
other things, the continuing growth of our currently marketed
products; developments with competitive products; the timing and
scope of regulatory approvals and the success of our new product
launches; asset impairments, restructurings, and acquisitions of
compounds under development resulting in acquired in-process
research and development charges; foreign exchange rates;
changes in effective tax rates; wholesaler inventory changes;
other regulatory developments, litigation, and government
investigations; and the impact of governmental actions regarding
pricing, importation, and reimbursement for pharmaceuticals. We
undertake no duty to update these forward-looking statements.